中国医药
中國醫藥
중국의약
CHINA MEDICINE
2014年
2期
173-176
,共4页
癌,非小细胞肺%放射疗法,调强适形%多西他赛
癌,非小細胞肺%放射療法,調彊適形%多西他賽
암,비소세포폐%방사요법,조강괄형%다서타새
Carcinoma,non-small-cell lung%Radiotherapy,intensity-modulated%Docetaxel
目的 评价胸部放疗序贯多西他赛化疗治疗老年局部晚期肺癌的效果.方法 收集2009年7月至2011年10月76例老年局部晚期非小细胞肺癌患者的病历资料进行回顾性分析,根据治疗方案不同分为放化疗组(37例)和放疗组(39例).放疗组采用适形调强放疗,60 Gy/30 f,放化疗组在放疗组同样方法的放疗结束后序贯多西他赛单药化疗4个周期.结果 治疗后6个月时,放疗组和放化疗组近期总有效率分别为59.0％ (23/39)和51.4％(19/37),组间差异无统计学意义(x2=0.053,P=0.819).放化疗组及放疗组的中位疾病进展时间分别为8.8及7.0个月,组间差异有统计学意义(x2=6.171,P=0.013);放化疗组及放疗组中位生存期分别为15.4及14.8个月,组间差异无统计学意义(x2=0.046,P=0.829).不良反应总体可耐受.结论 适形调强放疗序贯多西他赛化疗治疗老年局部晚期肺癌可延长疾病进展时间,但总生存未见明显改善,不良反应易于耐受.
目的 評價胸部放療序貫多西他賽化療治療老年跼部晚期肺癌的效果.方法 收集2009年7月至2011年10月76例老年跼部晚期非小細胞肺癌患者的病歷資料進行迴顧性分析,根據治療方案不同分為放化療組(37例)和放療組(39例).放療組採用適形調彊放療,60 Gy/30 f,放化療組在放療組同樣方法的放療結束後序貫多西他賽單藥化療4箇週期.結果 治療後6箇月時,放療組和放化療組近期總有效率分彆為59.0％ (23/39)和51.4％(19/37),組間差異無統計學意義(x2=0.053,P=0.819).放化療組及放療組的中位疾病進展時間分彆為8.8及7.0箇月,組間差異有統計學意義(x2=6.171,P=0.013);放化療組及放療組中位生存期分彆為15.4及14.8箇月,組間差異無統計學意義(x2=0.046,P=0.829).不良反應總體可耐受.結論 適形調彊放療序貫多西他賽化療治療老年跼部晚期肺癌可延長疾病進展時間,但總生存未見明顯改善,不良反應易于耐受.
목적 평개흉부방료서관다서타새화료치료노년국부만기폐암적효과.방법 수집2009년7월지2011년10월76례노년국부만기비소세포폐암환자적병력자료진행회고성분석,근거치료방안불동분위방화료조(37례)화방료조(39례).방료조채용괄형조강방료,60 Gy/30 f,방화료조재방료조동양방법적방료결속후서관다서타새단약화료4개주기.결과 치료후6개월시,방료조화방화료조근기총유효솔분별위59.0％ (23/39)화51.4％(19/37),조간차이무통계학의의(x2=0.053,P=0.819).방화료조급방료조적중위질병진전시간분별위8.8급7.0개월,조간차이유통계학의의(x2=6.171,P=0.013);방화료조급방료조중위생존기분별위15.4급14.8개월,조간차이무통계학의의(x2=0.046,P=0.829).불량반응총체가내수.결론 괄형조강방료서관다서타새화료치료노년국부만기폐암가연장질병진전시간,단총생존미견명현개선,불량반응역우내수.
Objective To study the efficacy and toxicity of thoracic radiotherapy alone and sradiotherapy with docetaxel for elderly patients with local advanced non-small cell lung cancer.Methods Seventy-six patients pathologically diagnosed of non-small cell lung cancer (NSCLC)were arranged into two groups randomly.One group received thoracic radiotherapy of 60 Gy which was divided into 30 fractions ; another received thoracic radiotherapy and sequential docetaxel chemotherapy for four cycles.Results Overall response rate was 59.0％ (23/39),51.4％ (19/37) respectively in radiotherapy group and radiochemotherapy group(x2 =0.053,P =0.819),no difference was observed between radiochemotherapy group and radiotherapy group.There was a significant prolong in progression free time which was 7.0 months and 8.8 months respectively(x2 =6.171,P =0.013),but no difference of overall survival was observed between two groups(x2 =0.046,P =0.829).Hematological toxicity occurred more in sequential chemoraditherapy groups.Conclusions Thoratic radiotherapy with docetaxel improve progression free time but not overall survival time.Its adverse effects are tolerable.
